Annual EBITDA
-$209.14 M
-$62.97 M-43.08%
31 December 2023
Summary:
Syndax Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$209.14 million, with the most recent change of -$62.97 million (-43.08%) on 31 December 2023. During the last 3 years, it has fallen by -$236.01 million (-878.40%). SNDX annual EBITDA is now -878.40% below its all-time high of $26.87 million, reached on 31 December 2021.SNDX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$84.10 M
-$16.09 M-23.65%
30 September 2024
Summary:
Syndax Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$84.10 million, with the most recent change of -$16.09 million (-23.65%) on 30 September 2024. Over the past year, it has dropped by -$11.69 million (-16.15%). SNDX quarterly EBITDA is now -187.42% below its all-time high of $96.20 million, reached on 31 December 2021.SNDX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$296.87 M
-$33.03 M-12.52%
30 September 2024
Summary:
Syndax Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$296.87 million, with the most recent change of -$33.03 million (-12.52%) on 30 September 2024. Over the past year, it has dropped by -$87.72 million (-41.95%). SNDX TTM EBITDA is now -1204.90% below its all-time high of $26.87 million, reached on 31 December 2021.SNDX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SNDX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -16.1% | -42.0% |
| 3 y3 years | -878.4% | -187.4% | -1204.9% |
| 5 y5 years | -273.8% | -531.0% | -436.1% |
SNDX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -878.4% | at low | -187.4% | at low | -1204.9% | at low |
| 5 y | 5 years | -878.4% | at low | -187.4% | at low | -1204.9% | at low |
| alltime | all time | -878.4% | at low | -187.4% | at low | -1204.9% | at low |
Syndax Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$84.10 M(+23.7%) | -$296.87 M(+12.5%) |
| June 2024 | - | -$68.02 M(-6.0%) | -$263.84 M(+9.7%) |
| Mar 2024 | - | -$72.34 M(-0.1%) | -$240.40 M(+14.9%) |
| Dec 2023 | -$209.14 M(+43.1%) | -$72.41 M(+41.8%) | -$209.14 M(+18.9%) |
| Sept 2023 | - | -$51.07 M(+14.6%) | -$175.88 M(+11.0%) |
| June 2023 | - | -$44.58 M(+8.5%) | -$158.46 M(+5.1%) |
| Mar 2023 | - | -$41.08 M(+4.9%) | -$150.74 M(+3.1%) |
| Dec 2022 | -$146.17 M(-644.0%) | -$39.15 M(+16.3%) | -$146.17 M(+1251.0%) |
| Sept 2022 | - | -$33.65 M(-8.7%) | -$10.82 M(-480.1%) |
| June 2022 | - | -$36.87 M(+1.0%) | $2.85 M(-83.7%) |
| Mar 2022 | - | -$36.51 M(-137.9%) | $17.45 M(-35.1%) |
| Dec 2021 | $26.87 M(-138.0%) | $96.20 M(-581.4%) | $26.87 M(-130.2%) |
| Sept 2021 | - | -$19.98 M(-10.3%) | -$89.10 M(+0.2%) |
| June 2021 | - | -$22.27 M(-17.8%) | -$88.90 M(+7.1%) |
| Mar 2021 | - | -$27.08 M(+37.0%) | -$83.03 M(+17.4%) |
| Dec 2020 | -$70.71 M(+26.4%) | -$19.77 M(-0.1%) | -$70.71 M(+10.0%) |
| Sept 2020 | - | -$19.78 M(+20.6%) | -$64.27 M(+12.1%) |
| June 2020 | - | -$16.40 M(+11.1%) | -$57.32 M(+2.7%) |
| Mar 2020 | - | -$14.76 M(+10.8%) | -$55.84 M(+0.8%) |
| Dec 2019 | -$55.95 M(-24.3%) | -$13.33 M(+3.9%) | -$55.38 M(-6.3%) |
| Sept 2019 | - | -$12.83 M(-14.0%) | -$59.10 M(-7.8%) |
| June 2019 | - | -$14.92 M(+4.3%) | -$64.12 M(-5.9%) |
| Mar 2019 | - | -$14.30 M(-16.2%) | -$68.15 M(-7.4%) |
| Dec 2018 | -$73.88 M | -$17.06 M(-4.4%) | -$73.60 M(-3.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$17.84 M(-5.9%) | -$76.03 M(+3.5%) |
| June 2018 | - | -$18.95 M(-4.1%) | -$73.48 M(+7.6%) |
| Mar 2018 | - | -$19.75 M(+1.3%) | -$68.30 M(+10.7%) |
| Dec 2017 | -$61.88 M(+41.7%) | -$19.49 M(+27.4%) | -$61.72 M(+15.9%) |
| Sept 2017 | - | -$15.29 M(+11.1%) | -$53.27 M(+0.1%) |
| June 2017 | - | -$13.77 M(+4.5%) | -$53.22 M(+10.7%) |
| Mar 2017 | - | -$13.17 M(+19.3%) | -$48.08 M(+10.3%) |
| Dec 2016 | -$43.68 M(+113.1%) | -$11.04 M(-27.5%) | -$43.61 M(+17.1%) |
| Sept 2016 | - | -$15.24 M(+76.6%) | -$37.25 M(+34.6%) |
| June 2016 | - | -$8.63 M(-0.8%) | -$27.68 M(+13.3%) |
| Mar 2016 | - | -$8.70 M(+85.9%) | -$24.42 M(+21.7%) |
| Dec 2015 | -$20.49 M(-3.9%) | -$4.68 M(-17.4%) | -$20.06 M(+7.5%) |
| Sept 2015 | - | -$5.67 M(+5.5%) | -$18.66 M(-10.0%) |
| June 2015 | - | -$5.37 M(+23.8%) | -$20.73 M(-4.4%) |
| Mar 2015 | - | -$4.34 M(+32.1%) | -$21.68 M(+1.7%) |
| Dec 2014 | -$21.32 M(+149.1%) | -$3.29 M(-57.5%) | -$21.32 M(+2.0%) |
| Sept 2014 | - | -$7.73 M(+22.3%) | -$20.91 M(+35.3%) |
| June 2014 | - | -$6.32 M(+58.9%) | -$15.46 M(+37.6%) |
| Mar 2014 | - | -$3.98 M(+38.4%) | -$11.23 M(+31.2%) |
| Dec 2013 | -$8.56 M(-1.6%) | -$2.88 M(+25.9%) | -$8.56 M(+50.6%) |
| Sept 2013 | - | -$2.28 M(+9.0%) | -$5.68 M(+67.1%) |
| June 2013 | - | -$2.10 M(+60.5%) | -$3.40 M(+160.5%) |
| Mar 2013 | - | -$1.30 M | -$1.30 M |
| Dec 2012 | -$8.70 M | - | - |
FAQ
- What is Syndax Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Syndax Pharmaceuticals?
- What is Syndax Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Syndax Pharmaceuticals?
- What is Syndax Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Syndax Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Syndax Pharmaceuticals?
- What is Syndax Pharmaceuticals TTM EBITDA year-on-year change?
What is Syndax Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of SNDX is -$209.14 M
What is the all time high annual EBITDA for Syndax Pharmaceuticals?
Syndax Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $26.87 M
What is Syndax Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of SNDX is -$84.10 M
What is the all time high quarterly EBITDA for Syndax Pharmaceuticals?
Syndax Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $96.20 M
What is Syndax Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, SNDX quarterly earnings before interest, taxes, depreciation & amortization has changed by -$11.69 M (-16.15%)
What is Syndax Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of SNDX is -$296.87 M
What is the all time high TTM EBITDA for Syndax Pharmaceuticals?
Syndax Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $26.87 M
What is Syndax Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, SNDX TTM earnings before interest, taxes, depreciation & amortization has changed by -$87.72 M (-41.95%)